Table of contents

Valve Durability in TAVR is a Critical Factor for the Future by Bart Meuris, M.D., Ph.D.

Bart Meuris, M.D., Ph.D.

University Leuven Hospital, Belgium

Aortic stenosis continues to be a major global healthcare issue, affecting 62 million people over the age of 65 years worldwide. Driving earlier intervention is a key focus for healthcare providers and policymakers. Consequently, the market for Aortic Valve Replacement (mainly Transcatheter Heart Valves) is expected to grow substantially over the coming years, rising from US $6 billion today to an estimated $US 7 billion by 2025.

Once reserved for high-risk elderly patients, there is growing evidence that the use of Transcatheter Aortic Valve Replacement (TAVR) is also safe and effective for lower-risk younger patients. However, the replacement valves in younger patients will need to endure much longer periods of use than that offered by current first-generation devices.

Admedus, a Minnesota-based company, believes it holds the key to the issue of longer-lasting valves: a single-piece 3D aortic valve that commences first-in-human studies this month. Admedus’ valve combines an innovative design with the company’s scientifically proven ADAPT® tissue technology.

The Admedus valve could significantly alter the TAVR landscape. It is widely accepted that the Transcatheter method of valve replacement (TAVR) is less invasive and less risky than the surgical alternative (SAVR). The ADAPT® treated valve developed by Admedus, offers a viable solution by providing significant anti-calcification properties. In addition, its unique design will deliver a stronger, more durable alternative, providing assurance that patients will be less likely to undergo repeat surgery due to deterioration of the replacement valve.


ADAPT® tissue technology offers the most advanced tissue science

The demand for a durable solution to aortic stenosis has led to a search for superior tissue science and valve design.

ADAPT® treated tissue is a completely Acellular Bovine Pericardial tissue with zero DNA and zero glutaraldehyde toxicity.

The ADAPT® tissue technology that forms the basis of Admedus’ single-piece valve has been used clinically in the CardioCel® and VascuCel® bioscaffolds developed and commercialized by Admedus. Based on 10 years of clinical data, the ADAPT® bioscaffold is the only material that does not calcify nor degrade. Approved by the US FDA and CE Mark since 2013, these products have been used in more than 20,000 procedures to date.

In June 2019, the peer-reviewed journal The Annals of Thoracic Surgery published data from an independent, multi-centre study involving 501 implants in pediatric patients. The data showed that the ADAPT® tissue was durable, with no evidence of calcification. Ninety-six percent of patients were free from re-intervention at three and five years after implant.

The ADAPT® single-piece 3D valve design reduces the leaflet stress by 35-40% and increases the coaptation significantly.  In laboratory tests, the Admedus valves were functional after 400 million cycles—equivalent to approximately 10 years of human use.

Pre-clinical sheep study provides confidence for the first-in-human study

The findings of Admedus’ 2019 pre-clinical study of the ADAPT® single-piece 3D valve in six juvenile sheep were presented earlier this year at PCR London Valves.

The sheep study demonstrated that the ADAPT® valve can be safely implanted and can deliver positive outcomes. The tissue on the valve was easy to handle during surgical implantation and there was no material failure or fatigue of the valve. The valve functioned normally following implantation. Echocardiography showed low gradients and no significant regurgitation across the implanted valves. Follow-up assessment six months later showed stable valve function.

It is reasonably expected that the ADAPT® single-piece 3D aortic valve will produce similar positive results in humans.  Consequently, a first-in-human trial with this prosthesis has been designed and is expected to commence in March 2020.

Up to 15 patients will be enrolled in the first-in-human study. The patients will undergo follow-up assessments for up to six months after receiving implantation of the ADAPT® single-piece 3D aortic valve. The results from the study are expected to be available between the first quarter of 2021 and the third quarter of 2021.

With durability remaining a key challenge in treating aortic stenosis patients, Admedus is well-positioned to offer AS patients a viable long-term solution.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Experts Views and Opinions

For this American Heart Month, Dr. Trotter is equipping Scribes with essential life-saving knowledge, providing CPR training and enabling them to make a meaningful impact during life or death situations. Read on.
Last year was one of the worst years ever for cyber attacks on healthcare organizations. According to John Riggi, national advisor for cybersecurity and risk for the American Hospital Association, the number of people affected by attacks broke records, with US federal data indicating that around 106 million people were impacted by a healthcare data breach, more than double when compared to 2022.
Moby Cutter™ is one of the safest surgical wire cutters on the market today! Their medical design team has over 35 years of experience performing surgical procedures in Hospitals, Emergency Rooms and Urgent Care Systems. It has been cleared for commercialization per FDA guidelines and sold as a prescription only (Rx) medical device. Dr. Stanley shares the advantages of the Moby Cutter.
Health systems continue to face ongoing pressures to reduce costs while maintaining quality patient care. With the average operating margin for hospitals at 0.84%, health systems are searching for ways to more effectively manage operating and capital budgets. However, gaps in data often hinder health systems by hiding cost burdens throughout the organization. These hidden costs limit health systems to finding one-time-savings without lasting relief from industry-wide pressures.
Healthcare organizations face many challenges: they must protect patient privacy, deliver quality care, and meet strict regulations. These organizations, which include medical device manufacturers, are trusted to safeguard incredibly sensitive information, a task that carries immense responsibility. Read on to learn what this industry expert has to say.

By using this website you agree to accept Medical Device News Magazine Privacy Policy